Please login to the form below

Not currently logged in
Email:
Password:

Dr Reddy's brings its generics portfolio to France

Continues the European roll-out of its oncology and anti-infective products

Dr Reddy's LaboratoriesDr Reddy's Laboratories will next month launch its generics portfolio in France as it continues to expand its European commercial operations.

The firm will introduce oncology and anti-infective generic products in the French hospital market, following their recent launch in the Spanish and Italian hospital markets.

Dr Reddy's is also looking to further strengthen its presence in Southern Europe - where its current portfolio spans gastrointestinal, cardiovascular, pain management, anti-fungal and dermatology products - with the introduction of HIV treatments in Italy and Spain later this year.

Adbijit Mukherjee, chief operating officer of Dr Reddy's, said: “It is our constant endeavour to enhance the reach of our affordable and difficult-to-produce drugs.

“Our business expansion in Europe is testimony to Dr Reddy's commitment to ensure access to affordable medicine for patients across the globe.”

The Indian pharma company's European operations are now based in Basel, after they moved to Switzerland from the UK around six years ago.

Meanwhile, in its home country it is targeting a number of therapy areas, having agreed a €118m deal with UCB in 2015 to acquire a portfolio of dermatology, respiratory and pediatric treatments. The market for this area is expected to grow by almost $40bn to reach $54bn by 2020.

Article by
Rebecca Clifford

9th February 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics